Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;114(1):120-129.
doi: 10.36660/abc.20190111.

Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future

[Article in English, Portuguese]
Sara Lopes Fernandes  1 , Rita Ribeiro Carvalho  1 , Luís Graça Santos  1 , Fernando Montenegro Sá  1 , Catarina Ruivo  1 , Sofia Lázaro Mendes  1 , Hélia Martins  1 , João Araujo Morais  1
Affiliations

Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future

[Article in English, Portuguese]
Sara Lopes Fernandes et al. Arq Bras Cardiol. 2020 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Pathophysiology of HFpEF - possible mechanisms involved. AF: atrial fibrillation; CAD: coronary artery disease; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; HFpEF: heart failure with preserved ejection fraction; HT: arterial hypertension; NO-cGMP-PKG: nitric oxide, reduced cyclic guanosine monophosphate and protein kinase G; PH: pulmonary hypertension; RAAS: renin-angiotensin-aldosterone system; RV: right ventricle.
Figure 2
Figure 2
Potential therapeutic targets and drugs evaluated in HFpEF. ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker; ARNI: angiotensin receptor neprilysin inhibitor; BB: Beta Blockers; MRA: mineralocorticoid receptor antagonists; PH: pulmonary hypertension.
See this image and copyright information in PMC

References

    1. Yancy CW, Januzzi JL, Allen LA, Butler J, Davis LL, Fonarow GC, et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2017;71(2):201–230. - PubMed
    1. Riet EE, Hoes AW, Wagenarr KP, Limburg A, Landman MA. Epidemiologia da Insuficiência Cardíaca: prevalência da insuficiência cardíaca e da disfunção ventricular nos idosos ao longo do tempo. Revisão sistemática. Rev Port Cardiol. 2017;36(5):405–407.
    1. Ponikowski P, Voors AA, Anker SD, Bueno Héctor, Cleland JGF, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200. - PubMed
    1. Altay H, Pehlivanoglu S. Heart Failure with Preserved Ejection Fraction. In: Kirali K, editor. Cardiomyopathies - Types and Treatments. IntechOpen; 2017. pp. 39–53.
    1. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–515. - PubMed

Publication types